

 <p>FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT</p>				ATTY. DOCKET NO.		APPLICATION NO.	
				18528.632		10/656,093	
				APPLICANTS			
				Andrew A. YOUNG <i>et al.</i>			
FILING DATE				GROUP			
September 5, 2003				To Be Assigned			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
BL	AAI	5,424,286	6/1995	Eng			
	ABI	5,512,549	4/1996	Chen			
	ACI	5,545,618	8/1996	Buckley			
	ADI	5,574,008	11/1996	Johnson			
	AEI	5,846,937	12/1998	Drucker			
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AFI	WO 98/05351	2/1998	PCT			Yes No
	AGI	WO 99/07404	2/1999	PCT			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AHI	Barragán <i>et al.</i> , "Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats", <u>Regulatory Peptides</u> , 67:63-68 (1996)					
	AII	Bhavsar <i>et al.</i> , "Inhibition of gastric emptying and of food intake appear to be independently controlled in rodents", <u>Soc. Neurosci. Abstr.</u> , 21:460 (188.8) (1995)					
	AJI	D'Alessio <i>et al.</i> , "Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons", <u>J. Clin. Invest.</u> , 97(1):133-138 (1996)					
	AKI	Edwards <i>et al.</i> , "Cardiovascular and Pancreatic Endocrine Responses to Glucagon-Like Peptide-1(7-36) Amide in the Conscious Calf", <u>Exp. Physiol.</u> , 82:709-716 (1997)					
	ALI	Eissele <i>et al.</i> , "Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide", <u>Life Sci.</u> , 55(8):629-634 (1994)					
	AMI	Eng <i>et al.</i> , "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom", <u>J. Biol. Chem.</u> , 265(33):20259-20262 (1990)					
	ANI	Eng <i>et al.</i> , "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom", <u>J. Biol. Chem.</u> , 267(11):7402-7405 (1992)					
	AOI	Fehmann <i>et al.</i> , "Stable Expression of the Rat GLP-1 Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-1(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39)", <u>Peptides</u> , 15(3):453-456 (1994)					
EXAMINER	/Leon Lankford Jr/					DATE CONSIDERED 07/10/2006	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

 <p>FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT</p>		ATTY. DOCKET NO. 18528.632	APPLICATION NO. 10/656,093
		APPLICANTS Andrew A. YOUNG <i>et al.</i>	
		FILING DATE September 5, 2003	GROUP To Be Assigned
		OTHER (Including Author, Title, Date, Pertinent Pages, etc.)	
BL	AA2	Ferguson <i>et al.</i> , "Cell-Surface Anchoring of Proteins via Glycosylphosphatidylinositol Structures", <u>Annu. Rev. Biochem.</u> , 57:285-320 (1988)	
	AB2	Göke <i>et al.</i> , "Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β -Cells", <u>J. Biol. Chem.</u> , 268(26):19650-19655 (1993)	
	AC2	Knudsen <i>et al.</i> , "Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration", <u>J. Med. Chem.</u> , 43:1664-1669 (2000)	
	AD2	Kolligs <i>et al.</i> , "Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9-39) Amide", <u>Diabetes</u> , 44:16-19 (1995)	
	AE2	Malhotra <i>et al.</i> , "Exendin-4, a new peptide from <i>Heloderma suspectum</i> venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini", <u>Regulatory Peptides</u> , 41:149-156 (1992)	
	AF2	Montrose-Rafizadeh <i>et al.</i> , "Structure-function Analysis of Exendin-4 / GLP-1 Analogs", <u>Diabetes</u> , 45(Suppl. 2):152A (1996)	
	AG2	O'Halloran <i>et al.</i> , "Glucagon-like peptide-1 (7-36)-NH ₂ : a physiological inhibitor of gastric acid secretion in man", <u>Journal of Endocrinology</u> , 126:169-173 (1990)	
	AH2	Ørskov <i>et al.</i> , "Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects are Indistinguishable", <u>Diabetes</u> , 42:658-661 (1993)	
	AI2	Raufman <i>et al.</i> , "Exendin-3, a Novel Peptide from <i>Heloderma horridum</i> Venom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas", <u>J. Biol. Chem.</u> , 266(5):2897-2902 (1991)	
	AJ2	Raufman <i>et al.</i> , "Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas", <u>J. Biol. Chem.</u> , 267(30):21432-21437 (1992)	
	AK2	Schepp <i>et al.</i> , "Exendin-4 and exendin-(9-39)NH ₂ : agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH ₂ ", <u>Eur. J. Pharm.</u> , 269:183-191 (1994)	
	AL2	Schjoldager <i>et al.</i> , "GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans", <u>Digestive Disease and Sciences</u> , 34(5):703-708 (1989)	
	AM2	Singh <i>et al.</i> , "Use of ¹²⁵ I-[Y ³⁹]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig", <u>Regulatory Peptides</u> , 53:47-59 (1994)	
EXAMINER		/Leon Lankford Jr/	DATE CONSIDERED 07/10/2006
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT 		ATTY. DOCKET NO.	APPLICATION NO.
		18528.632	10/656,093
		APPLICANTS	
		Andrew A. YOUNG <i>et al.</i>	
		FILING DATE	GROUP
		September 5, 2003	To Be Assigned
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
BL	AA3	Tang-Christensen <i>et al.</i> , "Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats", <u>Am. J. Physiol.</u> , 271:R848-R856 (1996)	
	AB3	Thorens <i>et al.</i> , "Expression cloning of the Pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1", <u>Proc. Natl. Acad. Sci. USA</u> , 88:8641-8645 (1992)	
	AC3	Thorens <i>et al.</i> , "Cloning and Functional Expression of the Human Islet GLP-1 Receptor", <u>Diabetes</u> , 42:1678-1682 (1993)	
	AD3	Turton <i>et al.</i> , "A role for glucagon-like peptide-1 in the central regulation of feeding", <u>Nature</u> , 379:69-72 (1996)	
	AE3	Wang <i>et al.</i> , "Glucagon-like Peptide-1 is a Physiological Incretin in Rat", <u>J. Clin. Invest.</u> , 95:417-421 (1995)	
	AF3	Wettergren <i>et al.</i> , "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man", <u>Digestive Diseases and Sciences</u> , 38(4):665-673 (1993)	
	AG3	Willms <i>et al.</i> , "Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients", <u>J. Clin. Endocrinol. Metab.</u> , 81(1):327-332 (1996)	
	AH3	Young <i>et al.</i> , "Preclinical Pharmacology of Pramlintide in the Rat: Comparisons with Human and Rat Amylin", <u>Drug Development Research</u> , 37:231-248 (1996)	
	AI3		
	AJ3		
	AK3		
	AL3		
	AM3		
EXAMINER		DATE CONSIDERED	
/Leon Lankford Jr/		07/10/2006	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			